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Abstract
Background: Hepatitis C virus infection (HCV) has a significant global health burden with an estimated 2%–3% of the
world’s population infected, and more than 350,000 dying annually from HCV-related conditions including liver failure and
liver cancer. Prisons potentially offer a relatively stable environment in which to commence treatment as they usually
provide good access to health care providers, and are organised around routine and structure. Uptake of treatment of HCV,
however, remains low in the community and in prisons. In this study, we explored factors affecting treatment uptake inside
prisons and hypothesised that prisoners have unique issues influencing HCV treatment uptake as a consequence of their
incarceration which are not experienced in other populations.
Method and Findings: We undertook a qualitative study exploring prisoners’ accounts of why they refused, deferred,
delayed or discontinued HCV treatment in prison. Between 2010 and 2013, 116 Australian inmates were interviewed from
prisons in New South Wales, Queensland, and Western Australia. Prisoners experienced many factors similar to those which
influence treatment uptake of those living with HCV infection in the community. Incarceration, however, provides different
circumstances of how these factors are experienced which need to be better understood if the number of prisoners
receiving treatment is to be increased. We developed a descriptive model of patient readiness and motivators for HCV
treatment inside prisons and discussed how we can improve treatment uptake among prisoners.
Conclusion: This study identified a broad and unique range of challenges to treatment of HCV in prison. Some of these are
likely to be diminished by improving treatment options and improved models of health care delivery. Other barriers relate
to inmate understanding of their illness and stigmatisation by other inmates and custodial staff and generally appear less
amenable to change although there is potential for peer-based education to address lack of knowledge and stigma.
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Introduction
Hepatitis C virus infection (HCV) has a significant global health
burden with an estimated 2%–3% of the world’s population
infected, and more than 350,000 dying annually from HCV-
related conditions including liver failure and liver cancer [1].
Prisons potentially offer a relatively stable environment in which to
commence treatment, organised around routine and structure,
and they usually provide good access to health care providers. The
potential exists to maximise compliance to HCV treatment
regimens [2]. It has been suggested that a new strategy for HCV
prevention, ‘Test and Treat’, should be implemented whereby
everyone within a certain age group in the high HCV prevalence
category is tested and linked to treatment if they are infected [3].
This approach could substantially reduce costs in the long term. In
addition, increasing HCV treatment within the prison setting
could potentially act as a prevention strategy by reducing the
prevalence of HCV in the injecting drug user population [4].
In Australia, HCV is the sixth most commonly notified
communicable disease with 226,700 people estimated to be living
with chronic HCV and is the primary cause of liver disease [5,6].
Recent studies indicate that one in five men in prison in Australia
(21%) and one third of women (34%) are HCV antibody positive
[7]. Uptake of treatment of HCV remains low in the community
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and also in the prison [7–9]. A national survey of prisoners
reported that only 5% of HCV positive prisoners had been treated
for HCV [7]. Almost half of all Australian prison inmates report
injecting drug use with around 70% incarcerated for drug-related
crimes [10]. Given this nexus, HCV infection is very common
among prisoners with an overall prevalence of 30%, and up to
80% among people who inject drugs (PWID) [11].
Standard care for the treatment of chronic HCV in Queensland
(Qld), New South Wales (NSW) and Western Australia (WA)
correctional centres during this study period was pegylated
interferon (PEG-IFN) and ribavirin (RBV). The length of
treatment was dependent on the HCV genotype: 48 weeks for
HCV genotypes 1, 4, 5, and 6 with expected sustained virologic
response (SVR) rates of 40%–50%; or 24 weeks (HCV genotype 2
and 3) and 80% SVR response rates [12]. This treatment regime
was the same as that available to the general population who met
the treatment criteria. Treatment could be deferred or delayed if
the patient exhibited contraindications such as: decompensated
liver disease, medical comorbidities which required medical
attention (e.g. cardiovascular disease, diabetes, epilepsy, uncon-
trolled depression), non-adherence to medical visits, or active drug
use [13–18].
A review of the literature highlights ‘readiness’ as an important
construct in an individual’s decision-making to undergo treatment
but there is little consensus on its definition [19–21]. In one study,
people with addictive behaviours were found to move through the
following stages of readiness and change: from pre-contemplation (no
intention to change) R contemplation (thinking of change) R
preparation for action (behaviour, experiences or environment) R
maintenance (prevent relapse and consolidate gains) [22]. Holt et al.
(2007) in a comprehensive review stated that: ‘‘Readiness occurs when
the environment, structure, and organizational members’ attitudes are such
that…[patients]…are receptive to a forthcoming change’’ (p.290) [23].
Models on barriers and facilitators to patient readiness and
HCV treatment uptake are mostly based on studies of people who
inject drugs (PWID) and other HCV infected individuals in the
community. Anderson (1995), for instance, focused on predispos-
ing and enabling patient characteristics (socio-demographics,
socioeconomics, substance use, mental health, structural, unstable
lifestyle) and perceived barriers and need (health beliefs, compet-
ing priorities, personal resources, perceived need, provider
evaluation) [24]. Others included treatment eligibility (modifiable
and non-modifiable treatment contraindications, liver disease,
genotype, comorbid conditions) and environmental barriers
(health insurance, physician access, transportation) [16].
In contrast, prisoners face unique challenges arising from the
prison setting that influence HCV treatment uptake and which do
not appear in any of the above models. Multiple barriers to
treatment uptake in prison have been reported including:
treatment refused due to short prison stays; the prison bureaucracy
delaying treatment; and prisoners refusing transfers to other
correctional facilities for treatment [25–28]. Enablers to treatment
included prisoners relinquishing their parole eligibility to com-
mence treatment inside prison [27]. Nevertheless, in common with
those infected in the community at large, prisoners also experience
poor access to treatment inside because of stigma, low screening
uptake rates, fears of the disease, and a lack of awareness and
knowledge about HCV infection and medical procedures [26].
Between 2010 and 2013, as part of the Hepatitis C, Prisons, and
Treatment Opportunities Study (HePATO), we interviewed
inmates diagnosed with HCV in Qld, NSW, and WA and
explored issues associated with HCV treatment uptake including:
awareness of HCV treatment services in prison, reasons for
deferring, delaying, refusing and discontinuing treatment, and
motivating factors to undergo treatment in prison. We triangulated
the data with perspectives from health service providers respon-
sible for delivering HCV treatment to prisoners.
Methods
Between 2010 and 2013, 116 inmates were interviewed from
prisons in NSW, Qld, and WA (Table 1). In addition, 29 health
professionals were interviewed in the three states who were directly
involved in HCV diagnosis and treatment programs inside prisons,
and six outside health professionals who were either associated or
involved in the education, care or follow up of prisoners with HCV
outside and within the prison system (Table 2).
Recruitment
To obtain an adequate cross-section of respondents, the
interviewers (LY & SC), prior to their visit, provided information
to prison nurses indicating the types of participants they wanted to
interview including gender, age group, Indigenous background
and HCV diagnosis and treatment status, as per the study
protocol. Specific exclusion criteria included inadequate profi-
ciency in English, inmates with severe mental health issues, and
inmates who on the advice of custodial staff may endanger the
safety of the interviewer. Initial recruitment was conducted
through the prison nurses who referred participants to researchers.
The most common reason for inmates not participating was prison
work or other activities taking priority. Some respondents were
called to the clinic but did not attend, even after agreeing to be
interviewed beforehand – the reasons for non-attendance were not
sought. The demographic characteristics of participants are listed
in Table 1.
On the day of the interview, inmates were contacted by a prison
nurse and asked to visit the prison clinic. The study was explained
in detail, and if agreeable, written consent was provided.
Interviews were digitally recorded in NSW and Qld, but
handwritten notes were taken in WA since digital recorders were
not permitted inside the prisons. Inmates who did not want to
participate or wanted to stop the interview at any time could do so
without penalty, they were not disadvantaged in their health care
or other services inside prison in any way. No remuneration was
given for participation. Interviews were conducted in private clinic
rooms or offices located within the prison accommodation area.
No custodial or clinic staff were present during the interviews, only
the prisoner and researcher. Video surveillance equipment without
sound enabled monitoring of the interviews to ensure the safety of
the researcher.
Prisons in NSW, Qld and WA varied in terms of the availability
of both HCV treatment and methadone treatment (Table 3). Of
the 16 prisons visited, two did not offer HCV treatment and five
prisons did not offer methadone treatment. Two different HCV
treatment models of care were observed: (a) a medical model of care
where treatment was initiated by prisoners visiting community-
based specialists, followed up and treated by a nurse and other
health providers in the prison system; and (b) a nurse-led model of care
(NLMC) whereby prisoners were assessed and managed largely by
skilled nurses in the prison system with more limited specialist
involvement (Table 3) and is described in more detail elsewhere
[29].
Data collection
Interview guidelines were developed and shared between the
trained interviewers (LY & SC) covering: experiences of living with
HCV; diagnosis and treatment experiences; perceived barriers to
treatment in prison; and opportunities for treatment (see Table
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Table 1. Socio-demographic profile of prisoners interviewed in New South Wales, Queensland and Western Australia for the
HePATO Study.
Characteristics NSW Qld WA TOTAL
Men Women Men Women Men Women Men Women
Gender 37 15 31 9 21 3 89 27
Age Group
21–30 12 1 9 5 6 3 27 9
31–40 17 6 8 2 8 - 33 8
.40 8 8 14 2 7 29 10
Indigenous status (Yes) 11 6 11 4 1 2 23 12
Education
Year 10 and below 30 9 27 6 15 2 72 17
Year 12 (HSC/TEE/TEA etc.) 1 3 2 - 3 - 6 3
Trade/professional qualification 4 2 2 1 3 1 9 4
University level 2 1 - 1 - - 2 2
Refused - - - 1 - - - 1
No. of times in an adult prison
Once 4 5 8 1 3 2 15 8
2 or more times 33 10 23 7 17 1 73 18
Other/Refused - - - 1 1 - 1 1
Current sentence
,12 months 1 3 2 1 2 - 5 4
1–5 years 14 6 11 4 11 2 36 12
.5 years 8 2 11 1 8 0 27 3
Not yet sentenced 14 4 7 2 - - 21 6
Other/Refused - - - 1 - 1 - 2
Treatment status in prison
Cleared naturally 1 - 3 2 - - 4 2
Treatment not offered or unavailable - - 5 3 2 2 7 5
Deferred/Delayed treatment 7 1 3 - - - 10 1
On waiting list 9 5 7 2 2 - 18 7
On treatment/Completed/Discontinued 12 6 9 - 15 1 36 7
Refused by medical staff 2 1 - - - - 2 1
Refused by prisoner (self) 6 2 4 2 1 - 11 4
Other/Refused - - - - 1 - 1 -
doi:10.1371/journal.pone.0087564.t001
Table 2. Prison health staff and other professionals interviewed in NSW, QLD and WA for the HePATO Study.
Interviews NSW QLD WA Total
Prison health professionals
Physician - 1 2 3
Nurse Unit Managers/Nursing Staff (Population, Mental Health, Hepatitis C, Primary Health
Care/Enrolled Nurses)/Clinical Nurse Consultants
15 5 5 25
Drug and Alcohol Counsellor 1 - - 1
Offender health services manager - 1 - 1
Outside health professionals
Justice Health Connections 2 - - 2
Community hepatitis C nurse - 1 - 1
Hepatitis Council - 3 - 3
doi:10.1371/journal.pone.0087564.t002
A Model of Hepatitis C Treatment Uptake in Prisons
PLOS ONE | www.plosone.org 3 February 2014 | Volume 9 | Issue 2 | e87564
S1). The average time of the recorded interviews among prisoners
was 44 minutes, ranging between 8 minutes and 2 hours. Health
professionals were asked about their experiences with prisoners,
what they perceived were the barriers to, and opportunities for
provision of treatment in prison. A grounded theory approach
informed the collection and analysis of qualitative data [30]. This
involved reading a textual database and exploring and discovering
categories, concepts and properties and their interrelationships
within the data.
Analysis
This qualitative analysis did not seek to obtain a representative
view, but rather to gather rich and complex data via in-depth
interviews in order to enrich the researchers’ capacity to
investigate and gain an understanding of respondents’ feelings,
opinions and feedback. Throughout the study, transcribed data
was coded within QSR NVIVO 9.0. The thematic coding
structure was revised as each interview was analysed. Analysis of
data ceased when thematic saturation was reached.
Human research ethics
Ethics approval was obtained from the Human Research Ethics
Committees at Curtin University in Perth, Western Australia
(HR201/2008), the Department of Corrective Services NSW (10/
10958), Justice Health NSW (D4578/10), Metro North Health
Service District in Queensland (HREC/10/QNRC/40), the
Aboriginal Health and Medical Research Council Ethics Com-
mittee of NSW (744/10), and ratified by the Human Research
Ethics Committee at the University of New South Wales, Sydney.
Results
A model of prisoners’ perceptions which influenced their
readiness to take up treatment in prison was developed to facilitate
our understanding of the complex and interactive nature of prison
HCV treatment uptake and its motivators (Figure 1). Multiple
domains of influence were evident with overlapping interrelation-
ships between the individual, their relationships, the organisation
(corrective and health services) and the community. We discussed
the model in relation to prisoners’ perceptions which led them to
delay, defer, refuse or discontinue treatment inside prison.
Individual level (Personal)
Stress. Stress, particularly on entry to prison, was common
among inmates. Stress symptoms included sleep disturbance, poor
concentration, and preoccupation with ongoing problems (AB,
female, 33 years, Qld). Prisoners were not interested in taking up
treatment if stressed by issues deemed to be more important than
HCV. As one mental health nurse explained:
…a lot of them don’t want to start treatment especially while they’re on
remand because of the stress of court… They want to be able to present
well when they go to court. Also family stresses…they can be under a
certain amount of stress and they don’t want any additional stress. They
want to be emotionally available if something’s going wrong with the
family. (Nurse, NSW)
Knowledge. Lack of awareness of HCV treatment in prison
was also a barrier among infected prisoners. Respondents knew
their HCV diagnosis from prison medical staff on entry, but some
had not had prison-based treatment fully explained. Only after a
period of incarceration (which varied from weeks to months or
even years) did they learn from other inmates, or a nurse that
treatment was available. Others did not have sufficient informa-
tion to decide on treatment or had been misinformed about
treatment. One inmate was unsure if the treatment was safe or not
(RT, male, 31 years, NSW), while another was misinformed about
the duration of treatment in prison (BW, male, 57 years, Qld).
Others were misinformed by their health care provider about
HCV such as being told that the disease was incurable (SN, male,
51 years, Qld) or too hard to treat (MA, male, 51 years, Qld).
In general, HCV treatment was not widely advertised inside
prisons. In one prison, medical staff explained why they did not
usually discuss HCV treatment on entry:
…if you suddenly put treatment in a booklet and people are seeing this,
they believe that that is their right to be given treatment […] And so you
don’t want to incriminate yourself because they will pick this up and
Table 3. Prisons visited as part of the HePATO Study.
Description NSW Qld WA TOTAL
Men Women Men Women Men Women Men Women
No. of prisons visited 5 2 4 1 3 1 12 4
No. of prisons with hepatitis C treatment 5 2 3 - 3 1 11 3
No. of prisons with methadone treatment 4 2 - 1 3 1 7 4
Models of hepatitis C treatment care
No. of prisons Nurse Led Model of Care 4 2 1 - 5 2
No. of prisons Medical Model of Care (Prison to
Hospital)
1 - 2 - 3 1 6 1
Prison classifications
Minimum/Low security 1 - 1 - 1 - 3
Medium 2 1 2 1
Maximum/High security/Maximum (Remand)/High
security (Remand)
1 1 3 1 1 - 5 2
Mixed (May Include Remand) 1 - 1 1 2 1
doi:10.1371/journal.pone.0087564.t003
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say, ‘‘Why didn’t I get treatment? It tells me here I have to have
treatment.’’… You’re better off leaving it as an open slate and then you
talk to them, and then you let them know that treatment is available if
they meet the criteria. (Nurse, Qld)
Perceptions of treatment. Individual understanding of
HCV disease and the effects of treatment were factors amongst
some prisoners refusing treatment. One inmate believed that he
could control his infection if he led a healthier lifestyle (CB, male,
51 years, NSW), while another thought that treatment would be
detrimental to his health (RM, male, 47 years, Qld). Another
perception was that HCV treatment regimens appeared to be
improving over time, with one inmate indicating that he was
‘‘hangin’ in there’’ (for better treatment) (FR, male, 37 years, NSW).
Another participant reported deferring treatment as he saw little
negative impact in being infected, he saw other infected people
who appeared healthy (KW, male, 25 years, NSW). While others had
a ‘did not want to know’ attitude since it would add to their worries
(MQ, female, 31 years, NSW).
Treatment related fears. Prisoners furthermore reported
fears associated with treatment. Inmates dreaded medical proce-
dures such as liver biopsies, the size of the needles associated with
interferon injections, or feared relapse to injecting drug use as a
consequence of injecting during treatment. Although liver biopsies
are no longer required for patients to qualify for treatment, one
inmate had delayed the decision to undertake treatment as she was
unsure of this (ER, female, 35 years, NSW). The size of venepuncture
needles and negative experiences with nurses trying to draw blood
for laboratory testing led some inmates to defer, delay, or refuse
treatment.
Well they find it very hard to get blood from me. Very, very, very hard to
take blood from me. They tried three times today and still couldn’t get no
blood, and… that was enough for me. (WG, female, 35 years,
NSW)
Other fears were related to inmates having to inject themselves
during treatment leading to drug relapse. These fears were usually
calmed by the prison nurse and patients subsequently underwent
treatment (Nurse, NSW).
Many reported fears of the adverse side effects of treatment,
including nausea, weight loss, and difficulties in conceiving
children after release. Prisoners recalled that these fears were
typically exacerbated by seeing, or being told of, bad side effects
experienced by others. Among men, weight loss was feared - one
inmate was afraid other prisoners might assume he was HIV
infected if he lost weight.
The weight loss. [ …But you gain that weight back again.] I know
but…you’ve got 300 blokes looking at you every day and…it’s not that
I really care what they think but there’s another fella, … I’ve seen him a
few times and … I’ve thought to myself, ‘‘He looks like he’s doin’ the
interferon treatment,’’ …‘cause he looked bad, you know. It makes you
look shockin’. People start thinking you’ve got AIDS or somethin’, you
know. (JB, male, 40 years, NSW)
Losing weight was regarded as contributing to vulnerability and
increasing the prospect of physical assault inside prison.
…to keep yourself safe from assault and victimisation, you have to keep
really fit and healthy… I’ve had people express that concern. One guy
stopped the treatment ‘cause he was having an enormous amount of
weight loss. (Nurse, NSW)
Otherwise, prisoners did not want their families to see them
looking sick and losing weight during prison visits, as they would
be forced to reveal that they were infected and undergoing HCV
treatment.
…their families don’t know they’ve got hep c and they don’t want their
family to know, so they don’t want to have the treatment. One guy said
to me…‘‘I don’t want to have the treatment ‘cause it’s going to make me
lose weight and look sick, and I don’t want my family to see me on visits
looking and feeling like that. (Nurse, NSW)
Amongst other prisoners, they did not want treatment since they
feared difficulty conceiving children with their partners after they
were released (FR, male, 37 years, NSW). A mental health nurse
observed that women, in particular, deferred treatment to have
children first.
Figure 1. A model of prisoner perceptions on the barriers and motivators for taking up hepatitis C treatment inside prison.
doi:10.1371/journal.pone.0087564.g001
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I’ve been told, there’s some…dynamics… of some of the relationships
can be, shall we say, interesting…. And, for some of the women, the
way they seal a relationship is by having a child with their partner. So
they want to have the child before they get treatment. (Nurse, NSW)
Individual level (Health)
Physical health. Some prisoners were not ready for treat-
ment as they thought that their HCV was not of the severity at
which treatment was necessary but would consider it if they
experienced worsening physical health.
[How come you’re not as interested?] Probably because I feel healthy. I
don’t know. […but you said you wanted to do a liver function test.]
Yeah, I just wanted to see if it was bad. Because if it is getting real bad
then I’ll see somebody about it, you know. Maybe get into treatment or
whatever. [..] But it isn’t really giving me any problems. (PV, male,
37 years, Qld)
Substance use. Many prisoners stated that it was pointless
getting on treatment if they were still using and sharing injecting
equipment or if they were still drinking when out of prison - since
these habits were detrimental to their liver and could lead to re-
infection if injecting.
No…I’ve never been on treatment, no. [Would you like to be on
treatment?] Yeah, I would but … I don’t want to go through something
full-on like that if I’m just going to share with someone again, you
know…[And you think you will be sharing with someone again?] Yeah,
probably…I don’t want to waste anyone else’s time and myself. (RT,
male, 26 years, Qld)
Physical safety. Other prisoners refused to be transferred to
another prison for treatment because of personal safety, refusing to
leave their current location which they regarded as home and a
place they felt safe.
… because they’re just such high profile classo [classified] patients
that they may not come out of [prison name] alive or they have
association problems. So the inmates [in the treatment prison] want
them elsewhere. So they’re here [in this prison] and they’re protected.
The other thing is that this is their familiar place – it’s become their
home…so we take them out of their home and move them to [treatment
prison name], they don’t cope well… Their coping skills are poor….So
they see it [current prison] as their home. When they leave the jail,
they’ve got to worry about who’s going to come up behind them (in
another prison). (Nurse, NSW)
Individual level (Socio-economic)
Employment and accommodation. Food and accommo-
dation are provided to all prisoners by corrective services but
prisoners can work to earn additional income which can be used to
pay for luxuries (e.g. tobacco). One prisoner (now on treatment)
had delayed her decision for fear of losing her job since treatment
would require taking time off work and waiting in the clinic to
consult a prison health care provider (KJ, female, 34 years, NSW).
Inmates were reluctant to transfer to another prison offering
treatment since they risked losing their preferred accommodation
and employment and having to work through the system again.
Relationship level (Family)
Family and relationships. Other prisoners refused treat-
ment because of family commitments on the outside. One refused
a transfer to consult a hepatologist since he was concerned about
his partner’s health and difficulties they would have with transport
to reach the (treatment) prison (MH, male, 44 years, NSW). While a
female inmate was concerned with having less energy to care for
her young children on the outside after being released and after
completing treatment in prison (WG, female, 35 years, NSW).
Organisation level (Health and Corrective Services)
Lack of continuity. Not all prisoners deferred, delayed or
refused treatment in prison. Some prisoners were highly motivated
and were proactive in seeking treatment inside prisons, but had
experienced delays.
Basically, I wanted to get on the program and get rid of the hep. […]
[But why did you wait so long? I mean it’s four years.] Oh I’ve asked
before [at the prison clinic]. [You’ve asked before? And what
happened then?] Nothin’ much… When I first come up here I asked
about it again, you know.… Just gets swept under the carpet. A couple
of years later, finally got going with it. [Why do you think there was a
change?] When someone dies I suppose people sit up and take notice.
(WJ, male, 52 years, Qld)
This lack of continuity might be due to the prison system itself.
During the interviews, many prisoners did not keep their
appointments at the prison clinic because of sudden prison lock
downs, prisoners being away for other activities (court appearanc-
es, legal interviews, or drug education courses), or prison officers
not informing the inmate they had been called. On the other
hand, prisoners may have decided not to attend clinic appoint-
ments, as told by one female prisoner:
… a couple of times too I didn’t go when they called…I refused a
couple of times, just couldn’t be bothered to go…[But if they told
you…?]…Yeah, if they’d told me I would have gone but a lot of the
time they don’t. They say, ‘‘You’ve gotta go to the clinic.’’ And I think
it’s either the psych [psychiatrist] or the physio (physiotherapist)…
and I think, ‘‘No, I’m not going’’…And [the prison nurse] gets the shits
and they end up calling me back up and saying, ‘‘Get your arse up
here.’’ Then I go. But I think it would have been a lot quicker to get
on treatment] if I showed up to all the appointments. (KJ, female,
34 years, NSW)
Another explanation may be that prisoners reported constantly
being transferred between prisons, and hence missing planned
follow-ups. These transfers were reported to be due to a multitude
of reasons, such as bed availability in prisons, court or medical
treatment in another town, prison re-classification, or as punish-
ment for behavioural infringements.
Waiting times. Other prisoners were deterred from under-
taking treatment because of the long waiting list (TT, female, 39
years, NSW), with one inmate reportedly having to wait two years
before commencing treatment (BW, male, 57 years, NSW). Prison
health care nurses (Qld, NSW, WA) explained that waiting times
were compounded by patient medical, mental or drug use
comorbidities. Comorbidities had to be addressed before they
could commence treatment or prisoners were placed on a
community-based hospital waiting list which could sometimes be
as long as two years. In NSW, sometimes nurses did not properly
complete the ‘waiting list entry’ form which followed prisoners site
A Model of Hepatitis C Treatment Uptake in Prisons
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to site and which might delay consultations with a nurse (Nurse,
NSW).
Hospital visits. In some centres gaining access to a specialist
physician for assessment meant many prisoners had to visit an
external hospital as there were no relevant specialists available at
the prison. For some prisoners, the initial experience of visiting a
hospital outside prison was a factor in their decision not to
continue with the pre-treatment work ups:
They wake you up at 4.00am in the morning here. Handcuff you…You
wait ‘til the officers do their rounds. Then they put you in a holding cell
‘til about 6.30am… The truck comes about 6.30am, 7.00am. So
you’re up at 4.00am. So you’ve sat in the jail here for three hours before
they move you…You get loaded onto the truck and they drop people who
are going to court at Roma Street and…to the [hospital name]…(at)…
8.30am, 9.00am. Then you just go in there and you wait…I saw the
doctor for 10 minutes…So I was away 14 and a J hours for a
10 minute appointment…You get back about 6.00pm… it’s…just a
terrible, terrible day. Plenty of blokes, they refuse to go. (ML, male, 52
years, Qld)
Staff access. Access to clinics varied between prisons. A
nurse in NSW thought that women’s prisons had better clinic staff
access than men’s prisons. One prisoner felt that prison officers
and nurses in some prisons had become desensitised and fatigued
by prisoners’ demands over the years to the point that requests
were sometimes ignored. This same prisoner had to wait until he
was in another prison which had good clinic staff access before he
pursued treatment.
You won’t get to the clinic in other gaols. It’s really hard.…you’ll get
some blokes that are here twice a day. ‘‘I need a Panadol. I need
something.’’… All the time … They’re constantly seeing the screws
[prison officers]. Constantly seeing the sweepers [cleaners]. ‘‘I
need, I need, I need …’’ That’s all you hear from them. [Nursing]
staff get pretty tired of hearing that all the time?… And then they abuse
them and carry on. (PW, male, 28 years, NSW)
Lack of care and support. Inmates believed that their
relatives or partner on the outside could provide better care and
support and they would have better food and showering facilities
while on treatment, providing a level of comfort not found in
prison while they experienced the worst of the treatment side
effects (FR, male, 37 years, NSW). No formal treatment support
groups or networks for prisoners were reported to exist in prison
but ad hoc support groups were formed among inmates who met
while waiting in the clinic before treatment or elsewhere.
… when she [nurse] told me…there was a chance that I could be sick
[from treatment] and how long it was going to take, I wanted to
leave [treatment] for when I got outside…so that I had a carer.
[…Who would… be your main carer then?] Well my family and my
girlfriend. [You didn’t want to do it inside?] That’s the thing about
inside… because it’s such a long period of 12 months, you know…
that’s long…I’ve seen some of the inmates that have had treatment.
They look pretty sick. (TN, male, 30 years, NSW)
Not being able to stay in their cell if they were sick was an issue
repeatedly raised by inmates in NSW who wanted treatment but
had made the decision to wait until they were released.
…I wouldn’t take the risk of gettin’ crook in gaol. Jail’s bad enough
without bein’ sick in here. [But if you were crook outside, wouldn’t that
be worse?] No, it’d be better. [In what way?…]if you’re crook [inside
prison], you can’t just stay in your room and sleep or whatever you
wanna do, you know. Things like that. Unless you’re near dyin’…
jail’s bad enough without feelin’ sick, you know…Unless you’re really
sick then you’ve gotta come and see the nurse, you’ve gotta get a thing
signed, and then they’ll lock you in your room for the rest of the day…
gaol’s horrible and you don’t wanna be sick while you’re in gaol. (AG,
male, 57 years, NSW)
Treatment eligibility. Inmates reported that they had
delayed or deferred treatment because of medical co-morbidities
(cancer, anaemia), psychiatric co-morbidities (depression) or drug
related co-morbidities (current injecting drug user). Furthermore,
some were on remand or had short sentences, and therefore did
not have enough time in prison to complete the treatment.
I started it in [prison name]. I started all the preliminaries in
[prison name] but I had to wait ‘til I got here before I could actually
get onto the program…And even then I had to jump up and down, and
scream. […How long did it take you to get on the program?] About 14
months….[…]If I’d have been able to kick off when I wanted to start
it…I would have been clean at [prison name] and not had to worry
about going through [another 3 prisons] before I could get on the
program…They wouldn’t let me…do the program while I was on
remand. I had to wait to be a sentenced prisoner…And that’s a bit of a
barrier ‘cause at the start, you wanna do it, you wanna do it, but keep
being told ‘no’ defeats you a little bit. (DR, male, 38 years, NSW)
Even if an inmate was eligible for treatment according to
standard treatment protocols, clinic staff may still not deem them
to be an acceptable treatment candidate. Clinic staff were
observed to initially screen HCV-infected prisoners based on their
sentenced/non-sentenced status, length of incarceration, current
injecting drug use, psychiatric comorbidities and other factors.
Some nurses decided that some inmates did not have enough time
before release to stabilise their addictions and psychiatric co-
morbidities, complete their pre-treatment workups, wait for
treatment (waiting list varied between several months and 2
years), and complete the 6- or 12-month course of combination
therapy of pegylated interferon and ribavirin.
Clinic staff therefore screened prisoners whom they believed
were more likely to complete treatment inside prison in order to
maximise limited resources and to report more successful
outcomes (i.e. completion of treatment). The option of inmates
continuing treatment outside of prison once released was rarely
discussed as staff believed that they frequently missed medical
appointments outside to deal with more important priorities like
employment, accommodation, drug use, and family. These were
seen as usually getting in the way of their treatment after release
(Two nurses, NSW).
Methadone. Some inmates refused treatment themselves
while others wanted to get on treatment but were refused by
health providers until they were drug-use abstinent or on a
methadone program to stabilise their addiction and injecting drug
use. Methadone was available in all three Australian states studied
except for men’s prisons in Qld and one prison in NSW where
methadone was banned by the prison management much to the
frustration of inmates who wanted treatment:
A Model of Hepatitis C Treatment Uptake in Prisons
PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e87564
Bring the program [methadone] back in and it’ll stop people using…
‘cause no-one’s gonna get on it [treatment] while they’re still usin’.
You know what I mean?…What’s the use? (KW, male, 25 years,
NSW)
Furthermore, methadone treatment policies in NSW meant
inmates had difficulty accessing the methadone treatment program
if they had not commenced such treatment in the community prior
to coming into prison.
Community level (Social and Cultural)
Stigma and discrimination. Willingness to go on treatment
was also affected by the shame and stigma of being an injecting
drug user, being infected with HCV, and being labelled ‘a junkie’,
fostered among the prisoners themselves – even by those who had
been or were current injecting drug users. Inmates therefore did
not want to talk openly about HCV with those they did not trust
and this led to uncertainty about having treatment in prison.
For some, having hepatitis C means you are a ‘junkie’ so most keep the
information private. (JL, male, 42 years, WA)
Others were hesitant about treatment since they felt shame in
being infected and were afraid of their family members’ reaction if
they found out.
Some of them their families don’t know that they’ve got hep c. Some of
them are ashamed of having hep c and on how they’ve caught it too…
their families don’t know that they’ve been using drugs. (Mental
Health Nurse, NSW)
Confidentiality. The lack of confidentiality was felt keenly
among patients who feel shame and stigma upon disclosure which
had an impact on their willingness to undergo treatment. Prisoners
usually lived together in close quarters and would see each other
every day. It was evident, in our interviews, that prisoners were
keenly observant of changes in another person’s health and
appearance, which could create suspicion, making it difficult for
the patient to keep his or her HCV status confidential. As one
prisoner on treatment pointed out,
…the poor blokes that have gotta do it [treatment] for a year, like you
start treatment and by the time you finish it everyone knows. You know
what I mean? … it may not be big in your eyes but to the person that’s
actually doin’ it, it’s pretty degrading. (SM, male, 33 years, NSW)
Lack of confidentiality can also be found among prison officers
and nurses. For example, this same inmate was asked by prison
officers what the medical issue was before being granted access to
the nurses in clinics. This can deter some prisoners who may
initially have wanted to seek treatment in prison.
…they [prison officers] want a reason … So they know why you’re
coming in that door. I have to physically say [to prison officers],
‘‘I’m coming here to have my hep c shot. All right? You happy now?’’
(SM, male, 33 years, NSW)
Whilst some nurses had a dismissive attitude believing that
‘everyone knows’ they are infected with HCV (Nurse, NSW).
Treatment motivators
Those on a waiting list, currently on treatment, or who had
completed treatment indicated that they were motivated to take up
treatment in prison, mainly due to concerns for the future. This
future was related to: their family, partners, children and
grandchildren; their health; release from prison; drug use
cessation; career goals; and the impact of life changing events.
Some were also motivated through the encouragement of the
prison nurse to accept treatment.
Protecting family and children. Protecting partners, chil-
dren and family from potential blood-borne viral transmission was
repeatedly mentioned by inmates as their main reason for wanting
treatment. They were afraid that they could transfer the virus to
their partner and to their children, particularly during rough play.
[And so this was last, this is just last week? So it’s pretty sudden isn’t it
wanting treatment when previously you did not care)?] Yeah. [How do
you feel about that?] Yeah, good. ‘Cause I got another kid coming on the
14th of March… [Why is that important?] Just so like if I have got
cuts and whatever on me I’m not gonna expose myself to them and that
sort of stuff. And catch it and that. (MV, male, 29 years, Qld)
For older inmates, being treated for HCV was important too.
One grandmother felt that with treatment she would be healthy
enough to raise her grandchildren outside. Another inmate said he
wanted to live longer and be able to see his grandchildren grow up.
I need to do it actually… ‘cause I want to be around when my little
grandkids grow up and they’re playing football and my grand-daughter’s
playing basketball, and my grandson’s boxing, you know. Yeah, I
wanna see that, yeah. (IT, male, 40 years, NSW)
Health and wellbeing. Even for prisoners without children
or family, their motivation to go on treatment was to prevent
HCV-related ill health and to prolong their life or to keep healthy.
Other inmates who sought treatment did so as they were already
experiencing ill health and symptoms from their infection (PH,
male 44 years, NSW; DC, male, 27 years, WA).
Career related. Getting healthy might not be the only
reason prisoners commence treatment. One inmate discussed his
future as a personal trainer after he was released and described his
perceived need to be rid of the disease so he could use steroids
without damaging his liver (NC, male, 27 years, NSW).
Life changing events, significant others and growing
old. Another group of prisoners appeared to have experienced
life changing events which served as motivators for taking up
treatment in prison after many years of deferring treatment. One
prisoner was motivated since he now had a partner and children
which led to additional responsibilities. He was also influenced by
a life shaping event to re-evaluate his lifestyle since he had lost his
mother to cancer while in prison, which forced changes in his
mental attitude towards his own health, lifestyle and criminal
activities (RT, male, 31 years, NSW). Growing old and ageing was
another motivating factor to commence treatment (SP, male, 44
years, WA).
Removing stigma, new start and being ‘clean’. Other
inmates commenced treatment to rid themselves of the ‘junkie’
stigma and reminders of their former drug use (AA, male, 28 years,
WA). These individuals said they wanted to be ‘clean’, and this had
physical and psychological consequences extending into the ‘right’
decisions they made into the future, particularly after release.
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[Is there a particular reason why you want to clear it?] I just don’t want
to have hep c. I don’t want that tag. [Is there some sort of stigma?]
Yeah, of course there’s a stigma…I hear that you got hep c. ‘‘Oh no,
you’re a junkie. (DR, male, 38 years, NSW)
Prisoners, particularly those who were about to be released,
believed that being treated would lead to a new start after prison,
and was part of their perception of being ‘clean’. Thus treatment
was one of the things which needed to be done to help build a new
future.
What made me do it?… I was doin’ long enough and I just had a
reality check. I wanted a new start I guess and that was one thing I
wanted out of me way. (PH, male, 44 years, NSW)
If I was never going to be released I would not get treated (prisoner now
on treatment and soon to be released). (GB, male, 33 years, WA)
Peer based knowledge. One Indigenous elder, in addition
to wanting treatment to be healthy and to see his grandchildren
grow up, mentioned that he wanted to help other Indigenous men
in prison. After going through treatment, he felt he would be able
to talk about his experiences to others and encourage them to go
on treatment (IT, male, 40 years, NSW).
Stop using drugs in jail. The majority of prisoners
interviewed did not want treatment if they were still using drugs
as they were at risk of being reinfected. However, one inmate
believed that being treated for HCV would encourage him to stop
using drugs inside jail (WS, male, 40 years, NSW).
Encouragement from nurses. In some prisons, nurses had
established good relationships and trust with inmates particularly
amongst those serving longer sentences and recidivist inmates who
consulted the same nurse for each incarceration episode. The
encouragement of a prison nurse was frequently described as a
factor among inmates and their acceptance to undergo treatment.
[…what took you over the line like from thinking about it to actually
doing it?] Oh, (the prison nurse was) always hassling me. Every time I
went in the clinic, she’s like, ‘‘K., come on, we’ve got to get you in here
and we’re going to do bloods.’’ (KJ, female, 34 years, NSW)
Discussion
This qualitative study, exemplified in the descriptive model
(Figure 1), provides insights into prisoners’ readiness and
experiences with HCV treatment in prison, as well as, their
decision to defer, delay, refuse or discontinue treatment. The
model also describes factors which motivated change and seeking
HCV treatment inside prison. Prisoners experienced many factors
similar to those which influence treatment uptake of those living
with HCV infection in the community [13,15,17,23,31–33].
Incarceration, however, provides different circumstances of how
these factors are experienced which need to be better understood if
the number of prisoners receiving treatment is to be increased.
The model describes how prisoners may not have necessarily
experienced difficulties in obtaining the necessities of daily living
whilst on treatment, but they nevertheless experienced unemploy-
ment, loss of income, and changes in accommodation – all of
which influenced treatment uptake, albeit under different circum-
stances to those relevant in the outside community. Ironically, in
an environment which is almost child-free, outside childcare
commitments and responsibilities impacted on the willingness of
women prisoners to accept treatment should they be released
early.
Prisoners’ attitudes, knowledge, perceptions and fears, and their
physical health and mental outlook influenced treatment uptake.
They lacked knowledge about HCV treatment and its availability
inside prison and did not have enough information about
treatment. They also had similar perceptions that treatment might
be detrimental to their health, and believed that they could self-
manage their disease by maintaining a healthier lifestyle. Many
types of fear led them to defer, delay, refuse or discontinue
treatment including, the fear of finding out if they were infected
with HCV, fear of drug relapse, fear of various types of medical
procedures, and fears related to the adverse side effects of
treatment such as feeling sick in prison, weight loss, and difficulty
conceiving children with their partner after release.
Like people infected with HCV in the community [31,34],
prisoners felt the shame and the stigma of being an injecting drug
user and being infected. They feared being labelled a ‘junkie’ by
inmates, being ‘unclean’, and were afraid of disapproval from
family members if it was discovered they are or were a drug user
and infected with HCV. This finding was unexpected given the
large numbers of injecting drugs users in prison and the high rates
of HCV. The stigma of being infected with HCV can lead to
reluctance to talk about the infection among prisoners, com-
pounded by the lack of confidentiality among prisoners, health,
and corrective service staff which may dissuade inmates from
taking up treatment inside prison.
Issues with health service delivery inside prison were similar to
those reported by individuals in the community [14,16,17,31,34–
37]. Prisoners experienced difficulties including, the lack of
availability of HCV treatment in some prisons, lack of continuity
by clinic staff, long waiting lists, the challenge of hospital visits for
specialist consultations, difficulties with clinic access, concerns with
the quality of care and support inside prison, and failure to
maintain confidentiality.
Issues unique to prisoners include those who reported not being
eligible for treatment by health care staff if they were on remand
or had sentences considered too short for the workup and time to
complete treatment. Furthermore, due to the prison environment,
they were subject to involuntary prison transfers, faced transpor-
tation challenges from prison to community-based hospitals, and
were subject to healthcare inequities such as, access to a
methadone or other opiate substitution treatment which was
available in the community but denied to prisoners in certain
jurisdictions due to corrective services policies or directives.
Another issue for prisoners was the myriad of stresses experienced
during the different stages of their incarceration. Prisoners
appeared to experience acute distress during the initial stages of
imprisonment which served to reduce the priority they placed on
health matters such as HCV treatment. For longer term inmates,
these stresses may continue for years depending on their phase of
incarceration.
Despite the many challenges posed by prison, many were
motivated to take up treatment mainly out of concerns for the
future. They took up treatment to prevent blood viral transmission
to their family and children after release, to live long enough to see
their children or grandchildren grow up, to become healthier, to
‘start’ a new life after release, as part of their career goals or a
different outlook due to life changing events. The encouragement
of the prison nurses was instrumental in inmates accepting
treatment.
It was evident that the prison environment exerted a significant
impact on health services and the lives of prisoners, which
overwhelmed any differences in gender, education, class, and
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ethnic or Indigenous background which may have influenced
treatment uptake in prison. Prisoners were all subjected to prison
routines and regulations which affected their treatment uptake in
varying degrees. Nevertheless, recommendations can be made to
improve treatment uptake inside prisons.
Better health and custodial collaboration and communications
may improve access to clinics and treatment, reduce the amount of
prison transfers, and improve confidentiality among staff. Nurse
led models of care such as that being implemented in NSW may
overcome barriers by reducing prison to community hospital visits,
improving the feelings of safety and comfort for some prisoners,
and maintaining family visits for prisoners who wish to remain in
the same prison and location.
In 2013, after the study data collection period, new therapeutic
agents, direct acting antivirals drugs (DAAs), were approved for
use in Australia for all genotypes and will be subsidised by the
Australian government Highly Specialised Drug (HSD). The
newly approved DAAs, used in combination with pegylated
interferon and ribavirin treatment are associated with better
treatment efficacy [38,39] and may increase the willingness of
inmates to take up treatment in Australian prisons. In the next 2–5
years oral (once-daily), tolerable, short-duration (12–16 weeks)
DAA treatments with extremely high efficacy (cure .90%) and
improved tolerability are likely to be approved for use in Australia
[40]. This is likely to address some of the concerns expressed by
prisoners in this study relating to side-effects.
Methadone should also be available to prisoners so that people
who inject drugs can stabilise or cease their injecting drug use,
reducing the potential for re-infection during and after treatment,
and improving prisoners’ eligibility for the treatment programs.
With better education and promotion, it is possible to increase the
knowledge inmates have on the availability of HCV treatment in
prison, leveraging off their desire for a better future for their
family, children and themselves.
Conclusion
This study identified a broad range of unique challenges to
treatment of HCV in prison. Some of these are likely to be
diminished by improving treatment options and improved models
of health care delivery. Problems with access to other relevant
health care (including but not limited to opioid maintenance
treatment and mental health care) and access to prison clinics
generally will require broad scale improvement to the health care
system inside prisons. Other barriers generally appear less
amenable to change and are related to inmates’ understanding
of their illness and stigmatisation by other inmates, custodial staff
and the community. Peer education and staff training, however,
may be able to address these challenges.
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